Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome

Background: The guideline-recommended low-density lipoprotein cholesterol target level of <70 mg/dL may not be achieved with statin administration in some patients with acute coronary syndrome (ACS). Therefore, the proprotein convertase subtilisin-kexin type 9 (PCSK9) antibody can be added to hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Satoshi, Sakamoto, Atsushi, Shoji, Satoshi, Kawaguchi, Yoshitaka, Wakabayashi, Yasushi, Matsunaga, Masaki, Suguro, Kiyohisa, Matsumoto, Yuji, Takase, Hiroyuki, Onodera, Tomoya, Tawarahara, Kei, Muto, Masahiro, Shirasaki, Yasutaka, Katoh, Hideki, Sano, Makoto, Suwa, Kenichiro, Naruse, Yoshihisa, Ohtani, Hayato, Saotome, Masao, Urushida, Tsuyoshi, Kohsaka, Shun, Okada, Eisaku, Maekawa, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219227/
https://www.ncbi.nlm.nih.gov/pubmed/37233171
http://dx.doi.org/10.3390/jcdd10050204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219227/
https://www.ncbi.nlm.nih.gov/pubmed/37233171
http://dx.doi.org/10.3390/jcdd10050204

Ejemplares similares